Fig. 1: In-cell protease (ICP) assay for screening inhibitors of SARS-CoV-2 proteases.
From: Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
a, b Constructs designed for the ICP assay containing mEmerald with nuclear localization signal (NLS), cleavage site for Mpro or PLpro, Zika virus NS2B followed by Mpro (a) or PLpro (amino acids 1541–1855 of nsp3) (b). c–f Localization of mEmerald-NLS (green) and ER marker mCherry-Sec61 β (red) at 6 h post-transfection and stained with nuclear stain Hoechst 33342 dye (blue), in ICP assay. c Cells transfected with ICP construct A, d cells transfected with ICP construct A with inactive Mpro mutant (C145A). e Cells transfected with ICP construct B, f cells transfected with ICP construct B with inactive PLpro mutant (C1651A).
